Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani… - Cancer treatment …, 2015 - Elsevier
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …
被引用次数：191 相关文章

[引用][C] Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani… - Cancer Treatment …, 2015 - cir.nii.ac.jp
Understanding and overcoming the mechanisms of primary and acquired resistance to
abiraterone and enzalutamide in castration resistant prostate cancer | CiNii Research CiNii …

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani… - CANCER TREATMENT …, 2015 - iris.unito.it
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia… - Cancer …, 2015 - cancertreatmentreviews.com
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia… - Cancer treatment …, 2015 - pubmed.ncbi.nlm.nih.gov
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …
[PDF] core.ac.uk

[PDF][PDF] Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani, P Bironzo… - core.ac.uk
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani… - Cancer Treatment …, 2015 - infona.pl
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.

C Buttigliero, M Tucci, V Bertaglia, F Vignani… - Cancer Treatment …, 2015 - europepmc.org
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …
[PDF] unito.it

[PDF][PDF] Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

C Buttigliero, M Tucci, V Bertaglia, F Vignani, P Bironzo… - 2023 - iris.unito.it
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …